Abstract:BACKGROUND: The CRISPR/Cas9 gene editing system was derived from a bacterial adaptive system mediated by the Clustered Regularly Interspaced Short Palindrome Repeats (CRISPR) and CRISPR‐associated proteins (Cas). Hematopoietic stem cells (HSCs) are easy to isolate and capable of self‐renewal and differentiation into different cell types, and have been successfully applied in the treatment of hematological malignancies and severe autoimmune diseases. In vivo and in vitro HSCs editing using the CRISPR/Cas9 system is a research trend that improves the therapeutic effect of HSCs transplantation, and has great clinical potential. OBJECTIVE: To review the disease therapeutics, delivery systems, gene editing and clinical application of CRISPR/Cas9 in HSCs transplantation. METHODS: The key words of “hematopoietic stem cells, CRISPR/Cas9, gene editing, delivery” in Chinese and English were used to search CNKI, PubMed and online databases respectively for relevant articles published from 2012 to 2018. After initial screening, the 61 eligible articles were further analyzed, summarized and concluded. RESULTS AND CONCLUSION: The simple and efficient gene editing ability of CRISPR/Cas9 can be applied to edit HSCs in vitro and in vivo and assist the clinical achievements of HSCs transplantation, which can reconstitute the life‐long repair of hematopoietic system in the blood and immune systems in patients with hematopoiesis deficiencies. The limited delivery vehicles of CRISPR/Cas9 system remain to be further studied and optimized. In addition, the ethical and safety issues of CRISPR/Cas9 system in clinical research of HSCs need to be considered. Funding: the National Natural Science Foundation of China, No. 81273576; Shanghai Scientific and Technological Innovation Project, No. 17431904500

Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells

Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy

Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation

Homology-Directed-Repair-Based Genome Editing in HSPCs for the Treatment of Inborn Errors of Immunity and Blood Disorders

Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders

Homology-driven Genome Editing in Hematopoietic Stem and Progenitor Cells Using ZFN Mrna and AAV6 Donors

Current approaches and potential challenges in the delivery of gene editing cargos into hematopoietic stem and progenitor cells

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.

An improved medium formulation for efficient ex vivo gene editing, expansion and engraftment of hematopoietic stem and progenitor cells

Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells

Therapy Development by Genome Editing of Hematopoietic Stem Cells

Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases

Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects

CRISPR/Cas9: research advances in hematopoietic stem cell transplantation

Comprehensive Update on Applications of CRISPR / Cas 9 for Hematological Diseases

Towards a Cure: Using Edited Hematopoietic Stem Cells

Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells

Gene therapy using haematopoietic stem and progenitor cells

Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned

Advancements in Hematopoietic Stem Cell Gene Therapy: A Journey of Progress for Viral Transduction